Consistently other reports show that cytotoxic activity of Bcl-2-inhibitors ABT-737 and ABT-199 (venetoclax) in primary CLL cells is significantly increased in hypoxia (compared to normoxia), importantly, overcoming the resistance towards chemotherapy under hypoxia [40]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.